³Ô¹ÏÍøÕ¾

As one of the greatest health challenges facing humanity, the antibiotics currently used to treat infections are becoming increasingly ineffective as bacteria continue to fight back and spread resistance.

OUTBREAK (One-health Understanding Through Bacterial REsistance to Antibiotics Knowledge) will be led by the University of Technology Sydney in collaboration with the University of Newcastle and 12 other partners.

The sophisticated system will combine machine learning, data and science to determine how AMR cycles through humans, animals and the environment.

and will head up the University of Newcastle team, offering their expertise in the areas of environment and better healthcare respectively.

“AMR is forecast to cause 10 million deaths annually by 2050 at a cost of US$100 trillion. In order to fight AMR, we need better intelligence as well as new weapons,” Professor Flynn said.

“OUTBREAK will be an Australia-wide system for tracing, tracking and addressing AMR to reduce hospital admissions, healthcare costs and ultimately prevent millions of deaths.”

With bacteria all around us, it’s important to understand how antibiotic resistance develops through environmental factors such as fertilisers and foodborne diseases, as well as human-to-human transmission.

By using data streams from people, animals and the environment, combined with AMR science, the technology will predict possible AMR outbreaks, determine the origin of outbreaks, and evaluate the risks and cost-effectiveness of treatments and intervention strategies.

“We need a holistic approach to extend the effectiveness of current medicines and to develop new treatments,” Professor Neilan said.

“This project will ensure the rapid translation of university-led research into the community to improve the health of all Australians.”

The project received almost $1 million funding through a Medical Research Future Fund (MRFF) Frontiers Grant, in addition to $1.4 million in contributions from partner organisations.

The project team will conduct initial research across the Illawarra-Shoalhaven region of NSW, with a second target region of Hunter New England.